Sixty Degree Capital focuses its investments on technology (AI, cybersecurity, digital infrastructure, SaaS) and healthcare (drug development, diagnostics, digital health, medical devices), investing from pre-seed to growth stages. Their strategy is thesis-driven, combining deep technical expertise, rigorous analysis, and operational support to back breakthrough opportunities.
57% of their portfolio is in Biotech & Life Sciences. They made 2 investments in the last 12 months. Their most common stage is series-b (57% of deals). Average disclosed round size is $107.2M (across 7 rounds with reported amounts).
Portfolio
7
Fund Size
$620M
Top Stage
Series B
Last 12 Mo
2
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
7 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Kinaset Therapeutics | Series B | $103M | Jan 2026 |
| AAAVantgarde Bio | Series B | $141M | Nov 2025 |
 Cato Networks | Growth | $238M | Sep 2023 |
 Bionaut Labs | Series B | $43.2M | Nov 2022 |
 Antios Therapeutics | Series B | $75M | Nov 2021 |
 GrubMarket | Series D | $90M | Dec 2020 |
| GrubMarket | Series D | $60M | Oct 2020 |
Top Co-Investors
Atlas Venture2 shared
Schroders Capital2 shared
Willett Advisors2 shared
GGV Capital2 shared
BlackRock2 shared
Trinity Ventures2 shared
Celtic House Venture Partners2 shared
Marubeni2 shared
RA Capital Management2 shared
Forbion1 shared
ATHOS1 shared
CDP Venture Capital1 shared
NEVA SGR1 shared
Lightspeed Venture Partners1 shared
SoftBank Vision Fund1 shared
Adams Street1 shared
Singtel Innov81 shared
Khosla Ventures1 shared
Deep Insight1 shared
OurCrowd1 shared
Last updated: 16 April 2026